Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares
Public ClinicalTrials.gov record NCT01459796. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to determine the safety and tolerability of rilonacept for participants with gout who were initiating allopurinol.
Study identification
- NCT ID
- NCT01459796
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 220 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2011
- Primary completion
- May 31, 2013
- Completion
- May 31, 2013
- Last update posted
- Jul 17, 2017
2011 – 2013
United States locations
- U.S. sites
- 74
- U.S. states
- 29
- U.S. cities
- 74
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Mesa | Arizona | — | — |
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Scottsdale | Arizona | — | — |
| Not listed | Sierra Vista | Arizona | — | — |
| Not listed | Tucson | Arizona | — | — |
| Not listed | Searcy | Arkansas | — | — |
| Not listed | Concord | California | — | — |
| Not listed | La Jolla | California | — | — |
| Not listed | Long Beach | California | — | — |
| Not listed | Whittier | California | — | — |
| Not listed | Denver | Colorado | — | — |
| Not listed | Trumbull | Connecticut | — | — |
| Not listed | Washington D.C. | District of Columbia | — | — |
| Not listed | Clearwater | Florida | — | — |
| Not listed | DeLand | Florida | — | — |
| Not listed | Delray Beach | Florida | — | — |
| Not listed | New Port Richey | Florida | — | — |
| Not listed | Ocala | Florida | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | St. Petersburg | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | Venice | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Boise | Idaho | — | — |
| Not listed | Coeur d'Alene | Idaho | — | — |
| Not listed | Meridian | Idaho | — | — |
| Not listed | Avon | Indiana | — | — |
| Not listed | Brownsburg | Indiana | — | — |
| Not listed | Evansville | Indiana | — | — |
| Not listed | Bowling Green | Kentucky | — | — |
| Not listed | Elizabethtown | Kentucky | — | — |
| Not listed | Owensboro | Kentucky | — | — |
| Not listed | New Orleans | Louisiana | — | — |
| Not listed | Cumberland | Maryland | — | — |
| Not listed | Hagerstown | Maryland | — | — |
| Not listed | Wheaton | Maryland | — | — |
| Not listed | Fall River | Massachusetts | — | — |
| Not listed | Edina | Minnesota | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Kalispell | Montana | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | Brooklyn | New York | — | — |
| Not listed | Cary | North Carolina | — | — |
| Not listed | Charlotte | North Carolina | — | — |
| Not listed | Greensboro | North Carolina | — | — |
| Not listed | Greenville | North Carolina | — | — |
| Not listed | Raleigh | North Carolina | — | — |
| Not listed | Salisbury | North Carolina | — | — |
| Not listed | Statesville | North Carolina | — | — |
| Not listed | Winston-Salem | North Carolina | — | — |
| Not listed | Akron | Ohio | — | — |
| Not listed | Carlisle | Ohio | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Huntingdon Valley | Pennsylvania | — | — |
| Not listed | Johnstown | Pennsylvania | — | — |
| Not listed | Pittsburgh | Pennsylvania | — | — |
| Not listed | Reading | Pennsylvania | — | — |
| Not listed | Anderson | South Carolina | — | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Columbia | South Carolina | — | — |
| Not listed | Greenville | South Carolina | — | — |
| Not listed | Rock Hill | South Carolina | — | — |
| Not listed | Simpsonville | South Carolina | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Fort Worth | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Lake Jackson | Texas | — | — |
| Not listed | North Richland Hills | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Sugar Land | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Arlington | Virginia | — | — |
| Not listed | Spokane | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01459796, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 17, 2017 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01459796 live on ClinicalTrials.gov.